Related Experiment Video

Updated: May 19, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements

Andrew Chase1, Catherine Bryant, Joannah Score

  • 1Faculty of Medicine, University of Southampton, Southampton, UK.

Haematologica
|August 10, 2012
PubMed

Insights

Ruxolitinib effectively inhibits the growth of cells with JAK2 fusion genes, showing promise for treating myeloproliferative neoplasms (MPN). This JAK1/2 inhibitor reduces proliferation and colony formation in JAK2-rearrangement positive cells.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • JAK2 fusion genes are rare but recurrent genetic abnormalities.
  • These abnormalities are linked to various, clinically heterogeneous hematologic malignancies.

Purpose of the Study:

  • To assess the efficacy of the JAK1/2 inhibitor ruxolitinib in treating myeloproliferative neoplasms (MPN) associated with JAK2 rearrangements.
  • To investigate the molecular mechanisms underlying ruxolitinib's action on JAK2-altered cells.

Main Methods:

  • In vitro studies using Ba/F3 cells engineered with ETV6-JAK2 fusions.
  • Assessment of ruxolitinib's effect on cell proliferation, survival, and signaling pathways (phosphorylation of JAK2, ERK, STAT5, AKT).
  • Ex vivo analysis of primary cells from patients with JAK2 rearrangements or amplification using methylcellulose assays and fluorescence in situ hybridization (FISH).

Main Results:

  • Ruxolitinib significantly reduced proliferation and survival of ETV6-JAK2 transformed Ba/F3 cells (IC50 = 370 nM).
  • Inhibition was linked to decreased phosphorylation of key signaling molecules including ETV6-JAK2, ERK, STAT5, and AKT.
  • Primary cells from patients with JAK2 rearrangements/amplification exhibited reduced colony growth in the presence of ruxolitinib compared to healthy controls.
  • FISH analysis confirmed reduced growth of JAK2-rearrangement positive colonies.

Conclusions:

  • Ruxolitinib demonstrates significant anti-proliferative and anti-survival effects on cells harboring JAK2 fusion genes.
  • The drug effectively inhibits relevant downstream signaling pathways.
  • Ruxolitinib represents a promising therapeutic option for patients with JAK2 fusion gene-associated hematologic malignancies, including MPN.

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...